KRT88P and liver disorder: The American Association for the Study of Liver Diseases Practice Guidelines indicate that the rates of HBV reactivation in transiently infected people (i.e., those negative for HBsAg and positive for anti-HBc and/or anti-HBs) receiving mild, moderate, and intense immunosuppressive therapy are 1.0–2.7%, 12%, and 14–20%, respectively, [14].